

**IXEKIZUMAB solution for injection (Taltz® ▼) for axial spondyloarthritis**

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of IXEKIZUMAB solution for injection (Taltz® ▼) for axial spondyloarthritis.**

**GREY**

Ixekizumab is indicated in the treatment of axial spondyloarthritis, which includes:

- > Treatment of adults with active ankylosing spondylitis (radiographic axial spondyloarthritis) who have responded inadequately to conventional therapy
- > Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)<sup>[1]</sup>

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of axial spondyloarthritis should continue to follow national guidance, local pathways and local formulary choices:

- > NICE Guideline NG65: [Spondyloarthritis in over 16s: diagnosis and management](#), last updated 02 June 2017
- > NICE Pathway: [Spondyloarthritis overview](#), last updated 12 June 2020
- > Pan Mersey APC Guideline: [Use of biological agents in the management of ankylosing spondylitis and non-radiographic axial spondyloarthritis](#), 31 January 2018
- > Pan Mersey APC Pathway: [Ankylosing Spondylitis \(AS\) and Non-Radiographic Axial Spondyloarthritis \(Axial SpA\) pathway](#), 28 November 2018

**References**

1. Eli Lilly and Company Limited. Summary of Product Characteristics, [Taltz 80 mg solution for injection in pre-filled pen](#), 02 June 2020. Accessed 08 July 2020.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.